Guillaume Joe Pegna

Dr. Guillaume Joe Pegna


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
KMKristen McClellan
Kristen McClellan
ECEmerson Y. Chen
Emerson Y. Chen
AKAdel Kardosh
Adel Kardosh
CLCharles D Lopez
Charles D Lopez
Jaydira Del RiveroJaydira Del Rivero
Jaydira Del Rivero
GPGuillaume Joe Pegna
Guillaume Joe Pegna
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogenous group of malignancies originating from neuroendocrine cells of the gastrointestinal tract, the incidence of which has been increasing for several decades. While there has been significant progress in the development of therapeutic options for patients with advanced or metastatic disease, these remain limited both in quantity and durability of benefit. This review examines the latest research elucidating the mechanisms of both up-front resistance and the eventual development of resistance to the primary systemic therapeutic options including somatostatin analogues, peptide receptor radionuclide therapy with lutetium Lu 177 dotatate, everolimus, sunitinib, and temozolomide-based chemotherapy. Further, potential strategies for overcoming these mechanisms of resistance are reviewed in addition to a comprehensive review of ongoing and planned clinical trials addressing this important challenge.

22 August 2024 in Current Problems in Cancer
Verified
Journal Article
Closed access
HMHannah S. McMurry
Hannah S. McMurry
JRJaydira Del Rivero
Jaydira Del Rivero
ECEmerson Y. Chen
Emerson Y. Chen
AKAdel Kardosh
Adel Kardosh
CLCharles D. Lopez
Charles D. Lopez
GPGuillaume Joe Pegna
Guillaume Joe Pegna